US pharmaceutical major Eli Lilly says it has completed its $400 million acquisition of Applied Molecular Evolution (Marketletter December 1, 2003).
AME stockholders will receive $18 for each share they hold in the form of cash, Lilly common stock or a combination of both. On the day of the announcement, February 12, the closing price of Lilly's common stock was $73.58 per share, resulting in an exchange ratio of 0.2446 of a Lilly share per AME share for those AME stockholders receiving the stock consideration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze